Kidney Transplant | Current Treatment | US | 2016
Each year in the United States, more than 17,000 patients suffering from renal failure undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, these patients must remain on immunosuppressive regimens for the duration of their life. This content stream explores the differences in prescribing practices, attitudes, and perceptions of the general nephrologists, transplant nephrologists, and transplant surgeons involved in kidney patients’ continuum of care and uncovers potential opportunities in the marketing of current and future immunosuppressant therapies.
Related Market Assessment Reports
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…
Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
Report
Obesity / Overweight – Current Treatment – Treatment Algorithms: Claims Data Analysis – Obesity / Overweight (US)
As the prevalence of obesity rises, the demand for safe and effective treatments increases. Therapies mimicking GLP-1 and GIP peptides—hormones that regulate appetite and energy metabolism—have…
